Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Capitalistaon Oct 03, 2023 1:36pm
169 Views
Post# 35667295

RE:RE:Deal or no deal!

RE:RE:Deal or no deal!I think a buyout at ANY price is many months away.  ONCY is just not behaving like a company seeking a buyout.  They are behaving much more like a company raising money to get through the next year or so.  

1.  They just did a $15 million private placement at a price much lower than the closing price at that time. This, predictably, tanked our SP.  There was no effort to support existing shareholders here. This could have been a rationalization that the shareholders (including ONCY mgmt personnel and BOD) will be rewarded once they get FDA approval for Pela.  
2.  They accepted a $5 million grant from PANCAN for an add-on trial.  I doubt that PANCAN would have granted this money if a buyout was imminent or even in consideration.  At the least, I'm guessing that PANCAN has a clause in the grant agreement that ONCY has to pay back some or all of that money if there is an acquisition within a specified time.   
3. The trial results over the past few years has been good enough that ONCY would have been the target of  DD efforts and likely acquisition offers by one or more BP companies.  That nothing has transpired looks to me like ONCY have just not considered any offer worth considering.  Or they have decided that their personal end prospects are better by not being acquired. 
4.  The continuing PR releases by FN Media Group are designed to attract potential new shareholders.  This fits in with and supports ONCY's other fundraising methodology (ATM sales).  

My working hypothesis is that ONCY is hoping to do the Precision Promise Phase III trial without benefit of a BP buyout.  And we'll see a Phase III mBC trial only if and when Pela is approved for PDAC.  I wish it were otherwise (I'd prefer a buyout myself), but I'm reading between the lines here. 
<< Previous
Bullboard Posts
Next >>